论文部分内容阅读
目的评价低分子肝素治疗急性脑梗死的疗效和安全性。方法将46例急性脑梗死患者随机分为治疗组和对照组各23例,对照组行常规治疗,治疗组在常规治疗基础上腹部皮下注射低分子肝素,根据神经功能缺损评分、凝血指标和不良反应评价疗效及安全性。结果临床疗效:对照组总有效率60.7%,显著优于治疗组(82.6%)。凝血指标:各项凝血指标均无显著性差异。不良反应:两组均无出血、血糖、血压、肝肾功能异常,对照组2例,治疗组1例过敏性红斑。结论适当剂量的低分子肝素治疗急性脑梗死安全有效,具临床推广价值。
Objective To evaluate the efficacy and safety of low molecular weight heparin in the treatment of acute cerebral infarction. Methods A total of 46 patients with acute cerebral infarction were randomly divided into treatment group (23 cases) and control group (23 cases). The control group received routine treatment. The treatment group received subcutaneous low molecular weight heparin on the basis of routine treatment. According to the neurological deficit score, Response to evaluate the efficacy and safety. Results Clinical efficacy: The control group, the total effective rate was 60.7%, significantly better than the treatment group (82.6%). Coagulation indicators: There is no significant difference between the coagulation indexes. Adverse reactions: No bleeding, blood glucose, blood pressure, liver and kidney dysfunction were found in both groups. Two cases in the control group and one case in the treatment group were allergic erythema. Conclusion The appropriate dose of low molecular weight heparin for the treatment of acute cerebral infarction safe and effective, with clinical value.